Published by Global Banking & Finance Review®
Posted on April 13, 2026
2 min readLast updated: April 13, 2026
Add as preferred source on GooglePolyPeptide Group AG, a Swiss peptide CDMO, is reportedly the target of potential take-private interest from private equity players EQT and KKR, with Advent also evaluating options. The company’s share price has risen ~20% this year to a market value near CHF 1 billion.
April 10 (Reuters) - Swiss contract drugmaker PolyPeptide Group AG is attracting potential takeover interest from private equity firms including EQT AB and KKR & Co., Bloomberg News reported on Friday, citing people with knowledge of the matter.
Here are some details:
• Advent has also been studying a possible acquisition of PolyPeptide, the report said.
• Any buyout firm pursuing a take-private deal could seek to collaborate with Swedish businessman Frederik Paulsen Jr., PolyPeptide's billionaire controlling shareholder, according to Bloomberg.
• Shares of PolyPeptide have risen nearly 20% this year, increasing the company's market value to about 1 billion Swiss francs ($1.3 billion).
• Deliberations are ongoing and there’s no certainty they will lead to a transaction, according to the report.
• The private equity companies declined to comment, Bloomberg said, while a spokesperson for PolyPeptide told the news agency that the company remained focused on executing its strategic plan.
(Reporting by Hyunsu Yim in Barcelona; Editing by Kirsten Donovan)
Private equity firms including EQT, KKR, and Advent have shown potential takeover interest in PolyPeptide Group.
PolyPeptide's market value has risen to about 1 billion Swiss francs (approximately $1.3 billion).
Deliberations are ongoing, and there is no certainty that they will lead to a transaction.
Swedish businessman Frederik Paulsen Jr. is the controlling shareholder of PolyPeptide Group.
Shares of PolyPeptide have risen nearly 20% so far this year.
Explore more articles in the Finance category
